PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumorsPLN-101095 accelerated ...

A clinical study testing a Pliant Therapeutics drug once considered a promising prospect for treating a fatal lung disorder is now on pause at the recommendation of independent outside observers.

SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics ...

Investors are swayed by Pliant Therapeutics’ data. The biotech posted early clinical evidence that its lead drug candidate reduces scarring and itching in a chronic liver disease, sending its share ...

Pliant Therapeutics Inc PLRX shares are volatile in Monday's after-hours session after the company announced a proposed $150 million offering. Pliant Therapeutics shares soared by nearly 160% during ...

Pliant Therapeutics (NASDAQ:PLRX) reported 12-week interim data for its drug bexotegrast's 320 mg dose group in a phase 2a trial to treat patients with a type of lung disease called idiopathic ...

Investors are excited about the biotech's prospects, but the company still has a long road ahead. Pliant raised $144 million in the IPO, which priced at the high end of the $14 to $16 range the ...

New phase 2 data of Pliant Therapeutics’ liver disease treatment shows that the highest dose was safe and effective at slowing progression relative to placebo, on par with lower dose data reported ...

(Crain's) — The head of association management firm SmithBucklin Corp. sold a Bucktown home for just under $1.5 million, about 17% less than the asking price of just under $1.75 million. Pliant to be ...

Pliant announced positive interim data from a phase 2a study of bexotegrast in treating idiopathic pulmonary fibrosis. The company also revealed plans to conduct a $250 million public stock offering.

Shares of Pliant Therapeutics Inc. jumped 41.6% in premarket trading on Monday after the company shared positive data from a Phase 2a clinical trial for its experimental idiopathic pulmonary fibrosis ...

SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics ...